AntriaBio snaps up $12M in private placement deal

An image of text of the definition of diabetes
AntriaBio snags $12 million in funding for diabetes drug.

AntriaBio ($ANTB), a biopharma focused on developing novel extended release therapies, has raised $12 million in a private placement deal.

The company said funds raised in the transaction will be used for general corporate purposes including preparation for Phase 1 clinical studies for AB101, its injectable once-weekly basal insulin for patients with type 1 and type 2 diabetes.

The funding round was led by pH Pharma, an affiliate of SBI Investment Korea, a venture capital firm that was spun out of SoftBank.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.

Since being founded in 2013, the Colorado-based AntriaBio has raised about $35 million through equity financings. In the most recent financing deal, accredited investors and institutions paid $1.10 for one share of common stock and received warrants exercisable for five years at $1.65 for one share of common stock.

"The additional capital provides us with resources to further our development of AB101, as well as to advance other potential long-acting product candidates in our pipeline,” said Nevan Elam, chairman and CEO of AntriaBio, said in a statement.

AntriaBio’ touts AB101 as an injectable once-weekly basal insulin for type 1 and type 2 diabetes in what it estimates to be an $11 billion market where the current standard of care is a once-daily basal insulin injection.

-here’s the release

Related Articles: 
Midatech mulls options after oral insulin flunks PhIIa